CONTEXT: Early diagnosis of gram-negative bloodstream infections, prompt identification of the infecting organism, and appropriate antibiotic therapy improve patient care outcomes and decrease health care expenditures. In an era of increasing antimicrobial resistance, methods to acquire and rapidly translate critical results into timely therapies for gram-negative bloodstream infections are needed. OBJECTIVE: To determine whether mass spectrometry technology coupled with antimicrobial stewardship provides a substantially improved alternative to conventional laboratory methods. DESIGN: An evidence-based intervention that integrated matrix-assisted laser desorption and ionization time-of-flight mass spectrometry, rapid antimicrobial susceptibility testing, and near-real-time antimicrobial stewardship practices was implemented. Outcomes in patients hospitalized prior to initiation of the study intervention were compared to those in patients treated after implementation. Differences in length of hospitalization and hospital costs were assessed in survivors. RESULTS: The mean hospital length of stay in the preintervention group survivors (n = 100) was 11.9 versus 9.3 days in the intervention group (n = 101; P = .01). After multivariate analysis, factors independently associated with decreased length of hospitalization included the intervention (hazard ratio, 1.38; 95% confidence interval, 1.01-1.88) and active therapy at 48 hours (hazard ratio, 2.9; confidence interval, 1.15-7.33). Mean hospital costs per patient were $45 709 in the preintervention group and $26 162 in the intervention group (P = .009). CONCLUSIONS: Integration of rapid identification and susceptibility techniques with antimicrobial stewardship significantly improved time to optimal therapy, and it decreased hospital length of stay and total costs. This innovative strategy has ramifications for other areas of patient care.
CONTEXT: Early diagnosis of gram-negative bloodstream infections, prompt identification of the infecting organism, and appropriate antibiotic therapy improve patient care outcomes and decrease health care expenditures. In an era of increasing antimicrobial resistance, methods to acquire and rapidly translate critical results into timely therapies for gram-negative bloodstream infections are needed. OBJECTIVE: To determine whether mass spectrometry technology coupled with antimicrobial stewardship provides a substantially improved alternative to conventional laboratory methods. DESIGN: An evidence-based intervention that integrated matrix-assisted laser desorption and ionization time-of-flight mass spectrometry, rapid antimicrobial susceptibility testing, and near-real-time antimicrobial stewardship practices was implemented. Outcomes in patients hospitalized prior to initiation of the study intervention were compared to those in patients treated after implementation. Differences in length of hospitalization and hospital costs were assessed in survivors. RESULTS: The mean hospital length of stay in the preintervention group survivors (n = 100) was 11.9 versus 9.3 days in the intervention group (n = 101; P = .01). After multivariate analysis, factors independently associated with decreased length of hospitalization included the intervention (hazard ratio, 1.38; 95% confidence interval, 1.01-1.88) and active therapy at 48 hours (hazard ratio, 2.9; confidence interval, 1.15-7.33). Mean hospital costs per patient were $45 709 in the preintervention group and $26 162 in the intervention group (P = .009). CONCLUSIONS: Integration of rapid identification and susceptibility techniques with antimicrobial stewardship significantly improved time to optimal therapy, and it decreased hospital length of stay and total costs. This innovative strategy has ramifications for other areas of patient care.
Authors: Blake W Buchan; Garrett C Reymann; Paul A Granato; Brenda R Alkins; Patricia Jim; Stephen Young Journal: J Clin Microbiol Date: 2015-10-14 Impact factor: 5.948
Authors: Conner Sothoron; Jason Ferreira; Nilmarie Guzman; Petra Aldridge; Yvette S McCarter; Christopher A Jankowski Journal: J Clin Microbiol Date: 2015-08-19 Impact factor: 5.948
Authors: Angela M Caliendo; David N Gilbert; Christine C Ginocchio; Kimberly E Hanson; Larissa May; Thomas C Quinn; Fred C Tenover; David Alland; Anne J Blaschke; Robert A Bonomo; Karen C Carroll; Mary Jane Ferraro; Lisa R Hirschhorn; W Patrick Joseph; Tobi Karchmer; Ann T MacIntyre; L Barth Reller; Audrey F Jackson Journal: Clin Infect Dis Date: 2013-12 Impact factor: 9.079
Authors: Andrea Bacconi; Gregory S Richmond; Michelle A Baroldi; Thomas G Laffler; Lawrence B Blyn; Heather E Carolan; Mark R Frinder; Donna M Toleno; David Metzgar; Jose R Gutierrez; Christian Massire; Megan Rounds; Natalie J Kennel; Richard E Rothman; Stephen Peterson; Karen C Carroll; Teresa Wakefield; David J Ecker; Rangarajan Sampath Journal: J Clin Microbiol Date: 2014-06-20 Impact factor: 5.948
Authors: R S Evans; J A Olson; E Stenehjem; W R Buckel; E A Thorell; S Howe; X Wu; P S Jones; J F Lloyd Journal: Appl Clin Inform Date: 2015-03-03 Impact factor: 2.342
Authors: Ritu Banerjee; Christine B Teng; Scott A Cunningham; Sherry M Ihde; James M Steckelberg; James P Moriarty; Nilay D Shah; Jayawant N Mandrekar; Robin Patel Journal: Clin Infect Dis Date: 2015-07-20 Impact factor: 9.079